Literature DB >> 18370877

Trans-scleral delivery of antiangiogenic proteins.

Anna M Demetriades1, Tye Deering, Hansheng Liu, Lili Lu, Peter Gehlbach, Jonathan D Packer, Feilim Mac Gabhann, Aleksander S Popel, Lisa L Wei, Peter A Campochiaro.   

Abstract

PURPOSE: In this study, we investigated the penetration of various proteins into the mouse eye after a periocular injection of the protein or an adenoviral vector (Ad) expressing the protein.
METHODS: At several time points after the injection, the retina, retinal pigmented epithelium/choroid, and sclera were dissected and enzyme-linked immunosorbent assays were performed.
RESULTS: After a periocular injection of AdsFlt-1.10, AdTGFbeta.10, or AdPEDF.11, choroidal levels of pigment epithelium-derived factor (PEDF) and transforming growth factor-beta (TGF-beta) were not significantly different from scleral levels, and choroidal levels of sFlt-1 (soluble Flt-1 or soluble VEGF receptor 1) were only moderately reduced from scleral levels, indicating that each of these proteins penetrate the sclera well. In contrast, retinal levels of each of the three proteins were low compared to choroidal levels, suggesting poor penetration into the retina. Levels of PEDF in the choroid peaked 2 h after a periocular injection of PEDF protein and returned to baseline between 6 and 24 h, and peak levels in the retina were 8.6% of peak choroidal levels. Levels of green fluorescent protein, a protein unlikely to have any binding sites in mouse tissues, peaked in the choroid 2 h after the periocular injection and were undetectable by 4 h, while peak levels in the retina were 64.3% of peak choroidal levels.
CONCLUSIONS: These data suggest that size and binding characteristics of proteins are likely to influence their ability to penetrate the eye from the periocular space, but in general, proteins as large as 50-75 kDa penetrate well into the choroid, but not into the retina. Periocular injections are feasible for the treatment of choroidal neovascularization with proteins or vectors that express them, but additional investigations are needed before they can be considered for treatment of retinal diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18370877     DOI: 10.1089/jop.2007.0061

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  14 in total

1.  Ex vivo permeation of erythropoietin through porcine conjunctiva, cornea, and sclera.

Authors:  Ana Paula Resende; Beatriz Silva; Berta São Braz; Telmo Nunes; Lídia Gonçalves; Esmeralda Delgado
Journal:  Drug Deliv Transl Res       Date:  2017-10       Impact factor: 4.617

2.  Sustained subconjunctival protein delivery using a thermosetting gel delivery system.

Authors:  Erin R Rieke; Juan Amaral; S Patricia Becerra; Robert J Lutz
Journal:  J Ocul Pharmacol Ther       Date:  2010-02       Impact factor: 2.671

3.  High-resolution photoacoustic imaging of ocular tissues.

Authors:  Ronald H Silverman; Fanting Kong; Y C Chen; Harriet O Lloyd; Hyung Ham Kim; Jonathan M Cannata; K Kirk Shung; D Jackson Coleman
Journal:  Ultrasound Med Biol       Date:  2010-05       Impact factor: 2.998

4.  Ocular delivery of pRNA nanoparticles: distribution and clearance after subconjunctival injection.

Authors:  Liang Feng; S Kevin Li; Hongshan Liu; Chia-Yang Liu; Kathleen LaSance; Farzin Haque; Dan Shu; Peixuan Guo
Journal:  Pharm Res       Date:  2013-12-03       Impact factor: 4.200

Review 5.  Ocular delivery of macromolecules.

Authors:  Yoo Chun Kim; Bryce Chiang; Xianggen Wu; Mark R Prausnitz
Journal:  J Control Release       Date:  2014-07-03       Impact factor: 9.776

6.  Characterization of human sclera barrier properties for transscleral delivery of bevacizumab and ranibizumab.

Authors:  He Wen; Jinsong Hao; S Kevin Li
Journal:  J Pharm Sci       Date:  2012-12-04       Impact factor: 3.534

7.  Effects of human recombinant PEDF protein and PEDF-derived peptide 34-mer on choroidal neovascularization.

Authors:  Juan Amaral; S Patricia Becerra
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-22       Impact factor: 4.799

8.  Management of Retinitis Pigmentosa via Platelet-Rich Plasma or Combination with Electromagnetic Stimulation: Retrospective Analysis of 1-Year Results.

Authors:  Umut Arslan; Emin Özmert
Journal:  Adv Ther       Date:  2020-04-18       Impact factor: 3.845

9.  Anti-inflammatory effect of pigment epithelium-derived factor in DBA/2J mice.

Authors:  Xiaohong Zhou; Feng Li; Li Kong; James Chodosh; Wei Cao
Journal:  Mol Vis       Date:  2009-02-27       Impact factor: 2.367

10.  Management of retinitis pigmentosa by Wharton's jelly-derived mesenchymal stem cells: prospective analysis of 1-year results.

Authors:  Emin Özmert; Umut Arslan
Journal:  Stem Cell Res Ther       Date:  2020-08-12       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.